A kinase inhibitor effectively blocks its target in vitro, but patients develop resistance within months. Systems pharmacology would attribute this primarily to:
AThe drug degrading too quickly in the bloodstream
BCompensatory activation of parallel signaling pathways that bypass the inhibited target, driven by feedback rewiring in the signaling network
CPatients not taking the drug as prescribed
DThe kinase target being unimportant for the disease
Network-level compensation is the primary mechanism of acquired resistance to targeted therapies. When a key signaling node is inhibited, negative feedback loops that normally restrain upstream receptors are released, leading to increased receptor activation and rerouting of signals through parallel pathways. For example, BRAF inhibition in melanoma relieves ERK-mediated negative feedback on receptor tyrosine kinases, activating the PI3K pathway as a bypass. Systems pharmacology models predict these compensatory responses by simulating the entire signaling network's dynamics, not just the drug-target interaction in isolation.
Question 2 True / False
Systems pharmacology aims to replace all experimental drug testing with computational predictions.
TTrue
FFalse
Answer: False
Systems pharmacology complements, not replaces, experimental testing. Computational models generate hypotheses about drug mechanisms, predict which combination strategies are most promising, and identify likely resistance mechanisms — dramatically narrowing the experimental search space. But models depend on incomplete network knowledge and estimated parameters, so predictions must be validated experimentally. The value is in prioritization: instead of testing thousands of drug combinations experimentally, systems pharmacology models can identify the most promising dozens, making drug development more efficient without eliminating the need for experimental and clinical validation.
Question 3 Short Answer
Why does systems pharmacology typically recommend drug combinations over single-agent therapy for diseases driven by signaling network dysregulation?
Think about your answer, then reveal below.
Model answer: Signaling networks have built-in redundancy and feedback loops that enable cells to compensate for inhibition of any single node. Blocking one pathway activates compensatory pathways through feedback rewiring, crosstalk, and parallel signaling routes. Combination therapy simultaneously blocks the primary target and its predicted compensatory escape routes, preventing the network from rerouting around the pharmacological blockade. Systems pharmacology models identify which combinations are synergistic — where the combined effect exceeds the sum of individual effects — by simulating network dynamics under multi-drug perturbations and finding the combinations that most effectively collapse the disease-driving signaling state.
Clinical examples validate this approach: combined BRAF + MEK inhibition in melanoma prevents the MAPK pathway reactivation seen with BRAF inhibition alone. Combined EGFR + MET inhibition prevents MET-mediated bypass of EGFR blockade. In each case, the combination targets were predicted from network models before clinical validation.